肝内胆管癌的肝切除与肝移植治疗
本文综述肝内胆管癌(iCCA)外科治疗进展。肝切除是主要治疗手段,但仅少数患者可手术,5年总生存率约25%-40%。对不可切除的极早期iCCA(≤2 cm),肝移植可能成为治疗选择,生存结局与肝细胞癌相当。
要点
- 肝切除是iCCA主要治疗手段,但仅少数患者适合手术。
- 淋巴结清扫至少获取6枚淋巴结被视为充分,因微观淋巴结转移见于超过40%患者。
- 不可切除的极早期iCCA(≤2 cm)可考虑肝移植,生存结局与肝细胞癌相当。
核心结论
- 肝切除是iCCA的主要治疗手段,但仅少数患者可手术,5年总生存率约25%-40%。
- 对不可切除的极早期iCCA(≤2 cm),肝移植可能成为治疗选择,生存结局与肝细胞癌相当。
- 对不可切除的晚期肝内局限肿瘤且对新辅助治疗持续缓解者,可考虑在前瞻性方案内行肝移植。
研究设计与样本
- 本文为综述,回顾iCCA外科治疗近期进展,并探讨其与局部区域治疗、辅助及新辅助策略的相关性。
主要发现
- 多数iCCA患者需行大范围肝切除以完整切除肿瘤。
- 淋巴结清扫至少获取6枚淋巴结被视为充分,因微观淋巴结转移见于超过40%患者。
- 当前肝切除后5年总生存率在25%-40%范围。
- 对不可切除的极早期iCCA(≤2 cm),肝移植的生存结局与肝细胞癌相当。
关键数值与推荐
- 淋巴结清扫至少获取6枚淋巴结被视为充分。
- 肝切除后5年总生存率范围为25%-40%。
- 微观淋巴结转移见于超过40%的患者。
- 极早期iCCA定义为≤2 cm。
临床怎么用
- iCCA可手术者以肝切除为主要治疗,需评估肝病背景与残肝体积以决定是否可行大范围肝切除。
- 手术时应行淋巴结清扫,至少获取6枚淋巴结。
- 对不可切除的极早期iCCA(≤2 cm),肝移植可作为治疗选择。
- 对不可切除的晚期肝内局限肿瘤且对新辅助治疗持续缓解者,可考虑在前瞻性方案内行肝移植。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The incidence of intrahepatic cholangiocarcinoma (iCCA) is increasing worldwide. Although several advances have been made in the past decades to better understand this complex malignancy and to develop new treatment strategies, the prognosis of iCCA remains dismal. Liver resection (LR) is the mainstay of treatment but only a minority of patients are amenable to surgery. In most cases, patients with iCCA will require a major hepatectomy for complete resection of the tumour. This may be contraindicated or increase the surgical burden in patients with chronic liver disease and small remnant liver volume. Lymphadenectomy with a minimal harvest of 6 lymph nodes is considered adequate, as microscopic nodal metastases have been shown in more than 40% of patients. Current 5-year overall survival following LR is in the range of 25%-40%. For locally advanced disease not amenable to upfront LR, neoadjuvant locoregional therapies may be used with the aim of converting these patients to resectability or even to transplantation in well-selected cases. Recent studies have shown that liver transplantation (LT) might be a treatment option for patients with unresectable very-early iCCA (i.e. ≤2 cm), with survival outcomes comparable to those of hepatocellular carcinoma. In patients with unresectable, advanced tumours, confined to the liver who achieve sustained response to neoadjuvant treatment, LT may be considered an option within prospective protocols. The role of adjuvant therapies in iCCA is still under debate. Herein, we review the recent advances in the surgical treatment of iCCA and examine its correlation with locoregional therapies, adjuvant and neo-adjuvant strategies.
引用
- Mazzaferro V, Gorgen A, Roayaie S, et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 2020. PMID: 31954498. doi:10.1016/j.jhep.2019.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。